cyclosporine, Restasis (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
PRESCRIBED FOR: Restasis ophthalmic emulsion 0.05% is an eye drop used increase production of tears in people with chronic dry eyes caused by inflammation associated with keratoconjuntivitis sicca. Restasis helps to increase tear production but does not work well in patients using anti-inflammatory eye drops or tear duct plugs.
SIDE EFFECTS: The most common side effect of cyclosporine ophthalmic emulsion is a temporary burning sensation in the eye. Other side effects include:
GENERIC AVAILABLE: No
PREPARATIONS: Ophthalmic emulsion (eye drops): 0.5 mg/ml cyclosporine. Restasis is supplied in a sterile, preservative-free single-use vial.
STORAGE: Restasis should be stored at room temperature, between 15 C to 25 C (59 F to 77 F).
DOSING: One drop should be instilled in each eye twice daily. Patients may use Restasis with artificial tears or over-the-counter eye lubricants, allowing a 15 minute interval between products.
Restasis should not be used while wearing contact lenses. Patients with chronic dry eye are generally advised not to wear contact lenses. If contact lenses are worn, they should be removed before applying Restasis. Lenses may be inserted 15 minutes after applying Restasis.
The safety and effectiveness of Restasis has not been established in children below the age of 16.
DRUG INTERACTIONS: The effectiveness of Restasis may be affected if administered with other eye drops. Patients using other eye drops should consult with their eye doctor for advice. Patients may use Restasis with artificial tears or over-the-counter eye lubricants, allowing a 15 minute interval between products.
PREGNANCY: Due to the lack of conclusive safety data, Restasis should be used in pregnancy only if clearly needed. Restasis is classified as FDA pregnancy risk category C (it caused harm in studies with animals, but use during pregnancy in humans has not been adequately evaluated).
Medically Reviewed by a Doctor on 9/28/2015
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions